Clinical trials: Carcinomas/Neoplasms
Head and Neck Cancer
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258310
- Testing
- capecitabine, Surgery, chemotherapy and/or radiotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Carcinoma in Situ, Transitional Cell Carcinoma
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin…
- Conditions
- Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT01310803
- Testing
- VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Thyroid Carcinoma, Anaplastic
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
The primary purpose of the study is to evaluate objective response rate ([ORR]: complete response [CR] and partial response [PR]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
- Trial name
- NCT02657369
- Testing
- Lenvatinib 24 mg
- Where
- 30 sites in United States, Australia and 3 more
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
To evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- DP-EN-RT (NCT01218594)
- Testing
- Endostatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic…
- Trial name
- NCT04785820
- Testing
- Lomvastomig, Tobemstomig, Nivolumab
- Where
- 52 sites in Argentina, Brazil and 16 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Renal Cell
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00334282
- Testing
- Pazopanib
- Where
- 99 sites in Argentina, Australia and 23 more
- Volunteers
- 435 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to characterize the effect of repeated oral administration of TAK-788 160 milligram (mg) once daily on the single oral and intravenous dose pharmacokinetics (PK) of midazolam.
- Trial name
- NCT04051827
- Testing
- Midazolam, TAK-788
- Where
- 8 sites in Australia, Netherlands and 1 more
- Volunteers
- 26 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT00391586
- Testing
- Erlotinib, Platinum-based chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- New Mexico Cancer Research Alliance
Recurrent Prostate Carcinoma
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance…
- Trial name
- NCT02488070
- Testing
- Computed Tomography, Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx), Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Breast Neoplasms, Secondary
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.
- Conditions
- Breast Neoplasms, Secondary, HER2 Positive Carcinoma of Breast
- Trial name
- IJBMNZrT003 (NCT01420146)
- Testing
- Zr89-trastuzumab
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
Breast Neoplasm Female, Breast Cancer
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
Breast conserving surgery (BCS) is performed on patients with breast cancer to resect and completely remove the cancer while conserving as much of the surrounding healthy tissue as possible.
- Trial name
- NCT04815083
- Testing
- Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- SBI ALApharma Canada, Inc.
Colorectal Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
- Trial name
- MIRACLEIII (NCT02694562)
- Testing
- 40um Embozene TANDEM Microspheres
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Cancer of the Bile Duct
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
- Trial name
- NCT02115542
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Oral Cavity
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21…
- Trial name
- INSPIRE (NCT02609386)
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Where
- 22 sites in United States, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Non Small Cell Lung Cancer
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
- Trial name
- NCT00364351
- Testing
- Vandetanib, Erlotinib
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 1,574 people
- Sponsor
- Genzyme, a Sanofi Company
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT03348631
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Where
- 581 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
TIL Therapy for Metastatic Renal Cell Carcinoma
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma.
- Trial name
- NCT02926053
- Testing
- Surgical removal of tumor tissue for T cell production, Cyclophosphamide, Fludarabine
- Where
- Denmark
- Volunteers
- 5 people
- Sponsor
- Inge Marie Svane
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.